FERM domain of Ezrin
(Plasmid
#62380)
-
PurposeExpresses the FERM domain of Ezrin (N terminal portion of the protein)
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 62380 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcDNA3.1
-
Backbone manufacturerInvitrogen
- Backbone size w/o insert (bp) 5428
- Total vector size (bp) 7095
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameEzrin aa1-309
-
Alt nameFERM domain of Ezrin (N terminal portion of the protein)
-
Alt nameEzrin
-
Alt nameEZR
-
SpeciesH. sapiens (human)
-
Insert Size (bp)888
-
Mutationcontains FERM domain of Ezrin (N terminal portion of the protein, aa's 1-309)
-
Entrez GeneEZR (a.k.a. CVIL, CVL, HEL-S-105, VIL2)
- Promoter CMV
-
Tag
/ Fusion Protein
- GFP (C terminal on backbone)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site EcoRI (destroyed during cloning)
- 3′ cloning site EcoRI (destroyed during cloning)
- 5′ sequencing primer CMV forward
- 3′ sequencing primer GFP reverse (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
FERM domain of Ezrin was a gift from Guillaume Charras (Addgene plasmid # 62380 ; http://n2t.net/addgene:62380 ; RRID:Addgene_62380) -
For your References section:
Quantitative analysis of ezrin turnover dynamics in the actin cortex. Fritzsche M, Thorogate R, Charras G. Biophys J. 2014 Jan 21;106(2):343-53. doi: 10.1016/j.bpj.2013.11.4499. 10.1016/j.bpj.2013.11.4499 PubMed 24461009